ImpediMed Ltd NCCN Investor Update Conference Call Transcript
Thank you for standing by. Welcome to the ImpediMed Limited conference call. (Operator Instructions) I would now like to hand the conference over to Mr. Rick Valencia, Managing Director and CEO. Please go ahead.
Thank you, Rachel. Welcome, everyone, and thank you for joining us today. We're hosting this conference call to discuss our recent announcement related to the NCCN Survivorship guidelines being updated to recommend regular screening for lymphoedema, including the bioimpedance spectroscopy, commonly referred to as BIS.
Joining me on the call today is Tim Cruickshank, Chief Financial Officer; and Frank Vicini. Dr. Vicini is an internationally recognized radiation oncologist. He has extensive experience in cancer clinical trial design and implementation. He is the former Chief Medical Officer of ImpediMed from 2014 to 2022 and remains a dear friend and adviser to the company. Dr. Vicini is currently the Global Chair of Breast Cancer Research and National Director of Breast Cancer Care
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |